Published in Lancet on May 24, 2003
Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol (2005) 9.13
Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A (2004) 8.38
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol (2004) 3.76
Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis (2010) 3.29
Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev (2005) 3.18
Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis (2004) 2.88
Relation between randomized controlled trials published in leading general medical journals and the global burden of disease. CMAJ (2004) 2.83
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol (2003) 2.77
Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci (2004) 2.45
Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol (2004) 2.45
Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol (2006) 2.44
The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ (2009) 2.35
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ (2003) 2.30
Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol (2004) 2.29
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol (2004) 2.21
Superspreading SARS events, Beijing, 2003. Emerg Infect Dis (2004) 2.03
Curtailing transmission of severe acute respiratory syndrome within a community and its hospital. Proc Biol Sci (2003) 2.02
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol (2005) 1.96
SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis (2004) 1.95
A new framework and software to estimate time-varying reproduction numbers during epidemics. Am J Epidemiol (2013) 1.94
Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol (2005) 1.93
Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A (2005) 1.85
Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol (2005) 1.79
Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol (2004) 1.78
Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol (2013) 1.76
Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol (2005) 1.76
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev (2007) 1.68
The severe acute respiratory syndrome coronavirus Nsp15 protein is an endoribonuclease that prefers manganese as a cofactor. J Virol (2004) 1.67
MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One (2009) 1.67
Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A (2004) 1.66
Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis (2004) 1.65
Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev (2015) 1.64
Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci U S A (2014) 1.63
Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol (2004) 1.62
Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol (2005) 1.61
Multiple organ infection and the pathogenesis of SARS. J Exp Med (2005) 1.58
Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis (2003) 1.57
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J Clin Microbiol (2004) 1.56
Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis (2004) 1.55
Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis (2003) 1.55
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep (2013) 1.55
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood (2005) 1.52
Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. J Virol (2008) 1.52
Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis (2004) 1.50
Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ (2004) 1.50
Wrestling SARS from uncertainty. Emerg Infect Dis (2004) 1.50
Cluster of SARS among medical students exposed to single patient, Hong Kong. Emerg Infect Dis (2004) 1.49
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog (2008) 1.47
Pro/con clinical debate: steroids are a key component in the treatment of SARS. Pro: Yes, steroids are a key component of the treatment regimen for SARS. Crit Care (2004) 1.45
SARS in hospital emergency room. Emerg Infect Dis (2004) 1.44
Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein. J Virol (2005) 1.43
Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol (2004) 1.42
Laboratory diagnosis of SARS. Emerg Infect Dis (2004) 1.41
Macaque model for severe acute respiratory syndrome. J Virol (2004) 1.41
Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR. J Clin Microbiol (2004) 1.41
A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol (2010) 1.40
Human bocavirus infection among children, Jordan. Emerg Infect Dis (2006) 1.40
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol (2004) 1.40
Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax (2003) 1.40
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol (2004) 1.39
Emerging pathogens: challenges and successes of molecular diagnostics. J Mol Diagn (2008) 1.38
Severe acute respiratory syndrome, Beijing, 2003. Emerg Infect Dis (2004) 1.37
Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci U S A (2006) 1.36
SARS outbreak, Taiwan, 2003. Emerg Infect Dis (2004) 1.35
Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. Proc Natl Acad Sci U S A (2006) 1.31
Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev (2012) 1.31
Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med (2006) 1.31
Role of China in the quest to define and control severe acute respiratory syndrome. Emerg Infect Dis (2003) 1.29
Mice susceptible to SARS coronavirus. Emerg Infect Dis (2004) 1.29
The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells (2014) 1.28
Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog (2010) 1.26
Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol (2005) 1.26
Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A (2004) 1.25
Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog (2009) 1.24
SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg Infect Dis (2004) 1.23
Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis (2005) 1.23
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax (2004) 1.20
Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr (2010) 1.19
Performance and Cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-pcr assays for detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol (2004) 1.19
Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis (2004) 1.19
Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog (2007) 1.16
Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis (2004) 1.16
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog (2011) 1.14
Clinical trials and novel pathogens: lessons learned from SARS. Emerg Infect Dis (2004) 1.14
The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis (2014) 1.14
Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis (2004) 1.13
Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol (2006) 1.12
Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis (2004) 1.12
Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol (2008) 1.12
Initial viral load and the outcomes of SARS. CMAJ (2004) 1.11
SARS transmission pattern in Singapore reassessed by viral sequence variation analysis. PLoS Med (2005) 1.11
Preclinical evaluation of two real-time, reverse transcription-PCR assays for detection of the severe acute respiratory syndrome coronavirus. J Clin Microbiol (2004) 1.10
Temporal variability and social heterogeneity in disease transmission: the case of SARS in Hong Kong. PLoS Comput Biol (2009) 1.09
Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 24.78
Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol (2001) 21.17
Enzymatic determination of total serum cholesterol. Clin Chem (1974) 20.65
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76
Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science (2003) 12.59
Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature (2005) 10.04
Human infection with influenza H9N2. Lancet (1999) 9.73
Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet (2004) 9.36
Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A (2006) 9.26
Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet (2002) 8.70
Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology (1998) 7.99
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A (2005) 7.12
H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A (2004) 6.61
Cocirculation of avian H9N2 and contemporary "human" H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment? J Virol (2001) 6.45
Organization of DNA sequences and replication origins at yeast telomeres. Cell (1983) 6.43
Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? J Virol (2005) 5.78
Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A (2000) 5.36
Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med (2006) 5.14
Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol (2005) 5.04
Reassortment of pandemic H1N1/2009 influenza A virus in swine. Science (2010) 4.92
Severe acute respiratory syndrome. Nat Med (2004) 4.75
Structure of the gene V protein of bacteriophage f1 determined by multiwavelength x-ray diffraction on the selenomethionyl protein. Proc Natl Acad Sci U S A (1994) 4.67
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet (1993) 4.51
Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A (2006) 4.49
Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res (2005) 4.41
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill (2013) 4.37
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA (1997) 4.37
Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology (2000) 4.37
Related chromosome binding sites for zeste, suppressors of zeste and Polycomb group proteins in Drosophila and their dependence on Enhancer of zeste function. EMBO J (1993) 4.26
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med (1995) 4.10
Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med (2007) 3.75
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (1997) 3.67
Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet (2003) 3.66
Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology (2006) 3.59
Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet (2004) 3.54
Unusual DNA sequences associated with the ends of yeast chromosomes. Nature (1984) 3.54
Identification of a novel coronavirus in bats. J Virol (2005) 3.48
Rho1p, a yeast protein at the interface between cell polarization and morphogenesis. Science (1996) 3.42
Prevalence and genetic diversity of coronaviruses in bats from China. J Virol (2006) 3.37
Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis (2002) 3.31
Intestinal inflammatory pseudotumour with regional lymph node involvement: identification of a new bacterium as the aetiological agent. J Pathol (2000) 3.20
Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? J Virol (2003) 3.15
The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol (2007) 3.12
Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis (1999) 3.11
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 3.11
Autonomously replicating sequences in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1980) 3.04
Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis (2000) 3.01
Avian influenza in Hong Kong 1997-2002. Avian Dis (2003) 2.90
Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet (2003) 2.84
Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol (2003) 2.77
Continuing evolution of H9N2 influenza viruses in Southeastern China. J Virol (2004) 2.75
The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 2.75
Molecular detection of a novel human influenza (H1N1) of pandemic potential by conventional and real-time quantitative RT-PCR assays. Clin Chem (2009) 2.68
Type 1 protein phosphatase acts in opposition to IpL1 protein kinase in regulating yeast chromosome segregation. Mol Cell Biol (1994) 2.59
Novel astroviruses in insectivorous bats. J Virol (2008) 2.48
Evolution and molecular epidemiology of H9N2 influenza A viruses from quail in southern China, 2000 to 2005. J Virol (2006) 2.47
Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet (2001) 2.37
Acinetobacter bacteremia in Hong Kong: prospective study and review. Clin Infect Dis (1999) 2.35
Molecular changes associated with the transmission of avian influenza a H5N1 and H9N2 viruses to humans. J Med Virol (2002) 2.35
Sli15 associates with the ipl1 protein kinase to promote proper chromosome segregation in Saccharomyces cerevisiae. J Cell Biol (1999) 2.32
Functional cooperation of Dam1, Ipl1, and the inner centromere protein (INCENP)-related protein Sli15 during chromosome segregation. J Cell Biol (2001) 2.31